Background: Blinding patients in clinical trials is a key methodological procedure, but the expected degree of bias due to nonblinded patients on estimated treatment effects is unknown. Methods: Systematic review of randomized clinical trials with one sub-study (i.e. experimental vs control) involving blinded patients and another, otherwise identical, sub-study involving nonblinded patients. Within each trial, we compared the difference in effect sizes (i.e. standardized mean differences) between the sub-studies. A difference <0 indicates that nonblinded patients generated a more optimistic effect estimate. We pooled the differences with random-effects inverse variance meta-analysis, and explored reasons for heterogeneity. Results: Our main analysis included 12 trials (3869 patients). The average difference in effect size for patient-reported outcomes was -0.56 (95% confidence interval -0.71 to -0.41), (I 2 ¼ 60%, P ¼ 0.004), i.e. nonblinded patients exaggerated the effect size by an average of
Introduction
A longstanding methodological ideal is to keep patients in clinical trials unaware of their allocated treatment. 1 Nonblinded patients, aware of their treatment, may differ from blinded patients in how they report symptoms or in the quality of the doctor-patient relationship, inducing dissimilar rates of, for example, co-intervention, attrition and placebo effect. 2 Patient blinding is thus strongly supported by tradition and theoretical considerations. However, the empirical foundation for this key methodological procedure is considerably less solid than often thought. [2] [3] [4] [5] [6] [7] Studies of the placebo effect and of blinding of outcome assessors provide circumstantial evidence, [3] [4] [5] [6] but the core empirical studies are large meta-epidemiological comparisons between double-blind trials and similar trials not double-blind. 7 An overview of seven meta-epidemiological studies reported an average 13% exaggeration of odds ratios in trials not double-blind, and a 22% exaggeration when outcomes were subjective. 7 Such between-trial analyses have a considerable risk of confounding, as the blinded trials may differ from nonblinded trials for many other reasons, for example how randomization was performed, sample size or multi-centre status. This problem is augmented by the limited number of adjustments possible for suspected confounders. Thus, in meta-epidemiological studies the association between lack of double-blinding and bias is not necessarily a causal one. In addition, the term 'double-blind' is ambiguous 8 and does not enable a clear distinction between the impact of patient blinding, and blinding of care providers and outcome assessors. What most meta-epidemiological studies address is blinding in a generic sense, not specifically the blinding of patients. It is therefore a cause of concern that the only metaepidemiological study we have identified that explicitly compared trials that blinded patients with similar trials that did not blind patients, reported a small average difference in effect size: -0.15 (95% confidence interval -0.39 to 0.09). The confidence interval overlapped the neutral result, and the difference disappeared when the authors adjusted for concealment of allocation. 9 It is clearly reasonable to suspect bias in randomized clinical trials with nonblinded patients. However, the average degree of bias is not known, nor is its range, variation or likely dependence on type of outcome. This is problematic because an estimate of the expected bias is important for: clinicians interpreting results from the numerous trials where patient blinding is not possible or has not been implemented; for reviewers assessing the risk of bias in trials included in a meta-analysis; 10 and for researchers who plan trials and are forced to balance the risk of bias with the practical challenges and increased cost of implementing patient blinding. Thus, we decided to systematically review clinical trials that randomized patients to blind and nonblind substudies. Our primary aim was to study the impact of lack of patient blinding on estimated treatment effects in randomized clinical trials; secondary aims were to study the impact on attrition rates and use of co-interventions.
Methods

Selection of studies
We included parallel group four-armed clinical trials that randomized patients to a blinded sub-study (experimental vs control) and an otherwise identical nonblind sub-study (experimental vs control). We also included three-armed trials with experimental and no-treatment groups and a placebo group portrayed to patients as another
Key Messages
• It is reasonable to suspect bias due to nonblinded patients in randomized clinical trials, but the typical degree of bias is not known.
• We reviewed randomized clinical trials with a sub-study involving nonblinded patients and an otherwise identical sub-study involving blinded patients, providing a reliable within-trial evaluation of the bias associated with lack of patient blinding.
• In 12 trials (3869 patients) with patient-reported outcomes, nonblinded patients exaggerated the standardized mean difference by an average of 0.56 standard deviation, but with considerable variation. In trials with a true moderate effect size of -0.5, nonblinded patients thus cause an exaggeration of the estimated effect by 112%.
• The degree of bias due to nonblinded patients in two non-acupuncture trials was less than in 10 acupuncture trials, and there was no indication of bias in two trials with outcomes assessed by blinded observers.
• Generalizability of the finding is restricted by all trials investigating complementary/alternative medicine interventions.
experimental group, i.e. patients were not informed about the possibility of a placebo intervention (nondisclosed placebo trial). This permitted the experimental group to be included both in a nonblind sub-study (experimental vs notreatment control) and a blind sub-study (experimental vs placebo control) ( Figure 1) . We call these studies main trials.
In other three-armed trials, patients were informed about the possibility of a placebo intervention (disclosed placebo trial). These trials therefore lack an experimental nonblind condition and this precludes a reliable estimation of the impact of patient blinding. We included such trials in the review for comparative reasons but not in the main analyses. We call these studies auxiliary trials.
We included trials with adequately concealed allocation (e.g. central randomization or envelope method). Trials were excluded if concealment of allocation was inadequate (e.g. day of month) or unclear. Pilot studies, cross-over trials and trials with split-body design were also excluded.
Patients were regarded as blinded when this was explicitly reported or when blinding was indicated by use of a placebo treatment (and if there was no indication of unblinding of patients). We excluded trials where the placebo treatment was used to blind patients to the hypothesis of the trial and not to the treatment they received.
Patients were regarded as nonblinded when explicitly reported to be so, or when lack of blinding was indicated by use of an untreated control group. We included only trials in which the experimental and control groups were intended to receive the same basic care.
Search strategy
We searched for the four-armed trials in: Medline, EMBASE and Cochrane Methodology Register (inception to March 2013). The search for three-armed trials was based on a re-assessment of trials included in a systematic review of placebo interventions 3 and a search in the three databases mentioned above (2008-12) (Appendix 1, available as Supplementary data at IJE online). Reference lists to included trials were read.
Eligibility and data extraction
Reports of potentially eligible trials were read in full by one author (F.E. or A.H.), and excluded if clearly ineligible. Two authors read all other trial reports in full (F.E. or S.B. and A.H.) and decided on inclusion independently. Disagreement was resolved by discussion. We extracted trial information using a pilot-tested data chart: clinical condition, type of intervention, number of sessions, length of treatment, type of placebo, type of notreatment, type of co-intervention, randomization method, number of patient randomized, content of information to patients and the blinding status of the treatment provider.
We also selected, if possible, four patient-reported measurement scale outcomes: a symptom-specific outcome [e.g. pain on a visual analogue scale (VAS)] and a global outcome (e.g. a quality of life score), timed at first posttreatment assessment and at last follow-up assessment. If possible, we also selected an observer-reported measurement scale outcome evaluated by blinded assessors, preferably timed at post-treatment. If more than one outcome in each category was eligible, we selected outcomes according to the following hierarchy: (i) primary outcome of the trial; (c) Three-armed trials with disclosed placebo (auxiliary trials). R, randomized; B, blinded; NB, non-blinded; E, experimental group; C: control group; C*, placebo control presented to patients as an experimental intervention; Ø, missing non-blind experimental group. In the three-armed trials with nondisclosed placebo, patients were not informed that the trial involved a placebo but instead led to believe that two experimental interventions were compared with a no-treatment control. Such trials are equivalent to four-armed trials as the patients in the experimental intervention group are blinded with regard to the nature of the 'experimental' interventions (one is in fact a blind control), and nonblinded with regard to whether they receive an experimental intervention or no intervention (no-treatment group). In the three-armed trials with disclosed placebo, patients were informed that the trial involved a possibility of receiving a placebo, and this implies a lack of a non-blind experimental group.
(ii) for symptom-specific outcomes, visual analogue scales; (iii) and for global outcomes, global assessments before quality of life measures [e.g. the short-form health survey (SF-36)]. We favoured the analysis population being asrandomized and only based on available patients (i.e. no imputations). The outcomes were selected by two authors (F.E. or S.B. and A.H.) independently and disagreements resolved by discussion.
We furthermore extracted the total number of patients in each group, the means and the standard deviations. If outcome data were missing or could not be calculated, we contacted trial authors, or used standard deviations from a similar trial with the same scale or baseline standard deviations. For trials reporting binary outcomes only, we converted odds ratios to standardized mean differences, assuming a logistic distribution, 10 and included the trials in a sensitivity analysis.
We also noted the number of drop-outs in each group (defined as number of patients unavailable for assessment) and also the number of patients in each group who used cointerventions (e.g. rescue medication), or the mean number of days (or dose or consultations) with such interventions.
Data analysis
The four-armed main trials enabled an assessment of the difference between the effect estimate based on blinded patients (blind sub-study) and the corresponding effect estimate based on nonblinded patients (nonblind sub-study).
Also three-armed main trials with nondisclosed placebo enabled an estimate of the impact of patient blinding. In such trials, all patients were aware of the distinction between the experimental intervention and the no-treatment control intervention, permitting a nonblind comparison (nonblind sub-study). Furthermore, those patients receiving an 'experimental' intervention were 'blinded' with respect to its type, which-unknown to the patients-included a placebo control, thus permitting a blind comparison between experimental and control (blind sub-study) ( Figure 1 ).
For each of the four-armed main trials, we calculated the difference in effect sizes [i.e. standardized mean differences (SMD)], dSMD: the SMD from the sub-study based on nonblinded patients minus the SMD from the sub-study based on the blinded patients. The standardization factor used was the pooled standard deviation based on the blinded patients. For the main three-armed trials, this indirect comparison is reducible to a direct comparison of placebo and notreatment. All within-trial comparisons were reported as dSMD, with a standard error calculated as described in Appendix 2 (available as Supplementary data at IJE online). A dSMD <0 indicates that nonblind patients generate more optimistic estimates of intervention effects.
We pooled the dSMDs from all trials using randomeffects inverse variance meta-analyses. For our main analysis we preferred symptom-specific outcomes assessed at post-treatment; but when such data were missing we used global assessment or follow-up data as available.
We subsequently studied whether the following factors impacted on our main result: type of outcome reporting; timing of the outcome assessment; type of patient-reported outcome; type of clinical condition; type of intervention; and trial characteristics (trial design, risk of unblinding, length of trial, risk of outcome selection bias).
Our secondary study aims involved assessing the impact of lack of blinding on rates of attrition and co-intervention. We therefore calculated the attrition risk in the control groups with blinded patients and with nonblind patients, and their ratio (control group attrition risk ratio).
We furthermore calculated the co-intervention rate in the control groups with blinded patients and with nonblind patients, and their ratio (control group co-intervention risk ratio). For trials reporting the mean use of co-intervention (e.g. mean days) we calculated the standardized mean difference between the control groups with blinded and nonblinded patients.
We also meta-analysed the auxiliary three-armed trials, i.e. patients were aware of the possibility of a placebo treatment. The comparison between placebo and no-treatment for these trials will likely underestimate the impact of patient blinding, and this auxiliary analysis served only as a benchmark for the likely minimal impact of patient blinding. Ethics committee approval was not necessary for this study.
Results
We inspected 2216 database hits and 234 trial summaries 3 and read 198 full-text publications. We excluded 166 studies, in most cases because they were not randomized clinical trials with adequate concealment of allocation or were not three-armed or four-armed trials (Appendix Figure 1 , available as Supplementary data at IJE online). Thus, we included 32 trials (7581 patients), 12 main trials [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and 20 auxiliary trials.
23-42
All 12 main trials (3869 patients) investigated complementary/alternative interventions, predominantly acupuncture (Tables 1 and 2 ). Patient-reported measurement scale outcomes were available for all trials; two trials also assessed observer-reported outcomes. 11, 20 Of the 20 auxiliary trials (3712 patients), four trials (150 patients) had incompletely reported outcomes. [38] [39] [40] [41] We thus had data from 16 trials, of which four trials were only included in sensitivity analyses, one trial because of borderline eligibility 38 (Appendix 3, available as Supplementary data at IJE online) and three trials because their binary outcomes had been converted to standardized mean differences. [35] [36] [37] Thus, 12 auxiliary trials were analysed in detail (Appendix Table 2 , available as Supplementary data at IJE online).
Main trials: primary results
The differences between effect sizes based on the 12 substudies with blinded patients and those of the corresponding sub-studies with nonblinded patients ranged from -0.12 to -1.06. The average effect size difference was -0.56 (95% confidence interval -0.71 to -0.41), with notable heterogeneity (I 2 ¼ 60%, P ¼ 0.004) (Figure 2 ). Thus, in trials with patient-reported outcomes, effect sizes based on nonblinded patients were exaggerated by an average of 0.56 standard deviation. For this main analysis, symptom-specific post-treatment outcomes were used in 10 trials. 11, [13] [14] [15] [16] [17] [18] [19] 21, 22 a global posttreatment outcome in one trial 12 and a symptom-specific follow-up outcome in one trial. 20 However, there was no clear tendency for results to differ depending on type of patient-reported outcome (Table 3) . Two main trials had outcomes assessed by blinded observers. 11, 20 One trial of Echinacea purpurea for the common cold reported a median (but not mean) increase in IL-8 with no clear difference in effect between the substudy with 350 blinded patients and the sub-study with 360 nonblinded patients. 11 Another trial 20 investigated the effect of acupuncture on mean TUG score (time to up and go in seconds) in 560 patients with osteoarthritis, difference in effect size -0.02 (-0.22 to -0.18) (Appendix 4, available as Supplementary data at IJE online). Differences in effect sizes for subgroups are presented in Table 3 . Two main trials were four-armed (1128 patients), and investigated the effect of distant healing for chronic fatigue syndrome 12 and Echinacea for the common cold.
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The average difference in effect size was -0.17 (-0.41 to 0.07), (I 2 ¼ 0%, P ¼ 0.69) ( Table 3 ). Ten main trials were three-armed (2741 patients) and investigated the effect of acupuncture on pain, nausea or anxiety. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The average difference in effect size was -0.63 (-0.77 to -0.49), (I 2 ¼ 43%, P ¼ 0.07).
Main trials: secondary results
Two main trials of short duration (2 weeks or less) had no drop-outs. 18, 22 The average risk of patient attrition in the nonblinded control groups of the 10 trials of medium to long duration (more than 2 weeks) was 7% (4% to 11%). The similar average blinded control group attrition risk was 4% (2% to 6%). The average ratio of control group attrition risk was 1.79 (1.18 to 2.70), i.e. the risk of patient drop-out was 79% higher in the nonblind control group as compared with the blinded control group. Based on the two main trials that provided binary cointervention data, 15, 16 more patients in the nonblind control group used co-intervention than in the blind control group, ratio of control group co-intervention risk 1.55 (0.99 to 2.43). Based on five main trials that provided measurement scale co-intervention outcomes, 13, 14, [17] [18] [19] the average use of co-intervention was also higher in the nonblinded control group, standardized mean difference -0.29 (-0.13 to -0.45)
Auxiliary trials
We analysed in detail 12 auxiliary trials (1536 patients) without a nonblind experimental condition (Appendix Table 2 , available as Supplementary data at IJE online), difference in effect size -0.26 (-0.37 to -0.16).
One of the 12 trials used blinded observers to assess outcomes, difference in effect sizes -0.06 (-0.57 to 0.45). 25 Two Patients were falsely informed that the trial compared two types of experimental interventions against a no-treatment control condition, i.e. the patients in experimental group were both blinded (regarding experimental vs nondisclosed placebo) and non-blinded (regarding experimental vs no-treatment control). International additional trials with binary outcomes, that we converted to effect sizes, also used blinded observers, difference in effect sizes 0.02 (-0.24 to 0.29) 35 and 0.02 (-0.54 to 0.58). 37 Differences in effect sizes for subgroups and for sensitivity analyses are reported in Appendix Table 3 (available as Supplementary data at IJE online). There were consistent differences in effect sizes for eight complementary/alternative trials, -0.29 (-0.44 to -0.14) and for four standard medical trials, -0.25 (-0.44 to -0.06).
Discussion
Based on 12 randomized clinical trials, lack of blinding of patients exaggerated effect sizes by an average of 0.56 (0.71 to 0.41) standard deviation when outcomes were patient-reported, but with considerable variation. No notable effect exaggeration was found in two trials when outcomes were assessed by blinded observers. All trials investigated complementary/alternative medical interventions, predominantly acupuncture. Average attrition rates were modest, but 79% (18% to 270%) higher in the nonblind control group. Co-intervention rates showed a similar pattern.
Study strengths and limitations
The strength of our study is the comparability of the involved groups and the distinct focus on patient blinding. The randomization of patients to blind and nonblind conditions avoided confounding by differences in patient prognosis and outcomes or unknown factors-a challenge for meta-epidemiological studies. 7, 9 In addition, selection bias was minimized as all trials had adequate allocation concealment and were generally large. In general, the trials were well planned and performed. Thus, observed differences in estimated effects, attrition rates and cointervention rates between the groups with blinded and nonblinded patients were, with a very high probability, related to their blinding status.
Assuming that the bias due to nonblinded patients in the included trials is comparable to that of ordinary twoarmed trials, our results may be extrapolated to acupuncture trials, and to complementary/alternative trials. We included no main standard medical trials, but analysis of the auxiliary trials found no clear difference between the degree of bias in eight complementary/alternative trials and in the four standard medical trials, indicating no marked difference in bias due to trial type. However, confidence intervals were wide, and extrapolation of our results beyond complementary/alternative trials may be problematic. Approximately 60% (i.e. the I 2 value) of the variation in the difference of effect sizes was caused by clinical or other systematic discrepancies between the trials. This degree of heterogeneity is usually considered moderate to substantial, 10 and unconditional pooling of results may be debated. We noted that the heterogeneity was quantitative (i.e. differed in degree, not in direction), pooled the results with a random-effects model and explored reasons for the heterogeneity. We found that acupuncture trials may have a more pronounced degree of bias than nonacupuncture trials, but it was not possible to clarify in more detail whether this difference was caused by type of intervention (non-pharmacological or pharmacological), trial design (three-or four-arm trial) or variation in patient expectations.
Other studies
Nü esch and colleagues 9 conducted a meta-epidemiological study of 16 meta-analyses of osteoarthritis trials, and reported only a small difference between trials with blinded patients and similar trials with nonblinded patients, difference in effect size -0.15 (-0.39 to 0.09). However, they also found larger effect size difference for nonpharmacological trials (-0.71), and for trials of pooled difference between standardized mean difference (SMD) based on blind patients and the corresponding SMD based on nonblind patients (95% confidence interval)-a dSMD <0 indicates than nonblind patients generate more optimistic estimates of intervention effect; complementary/alternative interventions (-0.48) , similar to what we found. The discrepancy between our pooled results may thus be caused both by a different sample of trials or by confounding in the study by Nü esch and colleagues.
On average, nonblinded observers in randomized clinical trials with subjective outcomes exaggerate effect sizes by -0.23 (-0.40 to -0.06). 5 In trials with patient-reported outcomes, patients can be considered introspective outcome assessors of their private symptoms. Thus, it appears that trials with nonblinded patients assessing their own symptoms may cause a higher degree of bias compared with trials with nonblinded observers assessing subjective outcomes. Meta-epidemiological studies have analysed other types of bias, for example single-centre status or patient exclusions, and have reported effect size difference that were much smaller than what we have found for lack of patient blinding: single-centre status -0.08 (-0.17 to 0.01) 43 after adjustment for sample size, and patient exclusions -0.13 (-0.29 to 0.04). 44 
Patient blinding and trial aims
The aim of many randomized clinical trials is predominantly explanatory, 45 i.e. to assess the effect of a clearly defined causal component of an intervention (for example a molecule with possible antibiotic properties) under ideal conditions. Such trials are often described as assessing 'efficacy' 46 or 'specific effects' 47 and to prioritize 'internal validity'. 48 In a trial with a predominantly explanatory aim, patient blinding adheres to the experimental ideal of keeping all factors equal except the causal component under investigation. For the purpose of our investigation, we regarded all sub-studies as having a mainly explanatory aim, and our results are therefore mainly relevant for such trials. However, the aim of some randomized trials is mainly pragmatic, i.e. to evaluate the effect of an intervention package in a setting as close to the practical clinical context as possible. Such trials are often described as assessing 'effectiveness', 46 may include 'non-specific effects' 47 and prioritize 'external validity'. 48 In such trials, patient blinding is sometimes implemented to protect against response bias when outcomes are patient-reported. 49 However, patient blinding may interfere with the overall pragmatic aim of the study. For example, attrition rates and co-intervention rates may simultaneously be considered causes of bias and consequences of the intervention. Similarly, placebo effects, or 'unspecific effects', 3,47 may be characterized as bias or clinical effects depending on perspective. None of the trials included in our review explicitly characterized the aim of their sub-studies as either explanatory or pragmatic. Many trials will not fall neatly into a binary classification of 'pragmatic' vs 'explanatory'. The concepts are probably best considered as describing a 'multidimensional continuum', 50, 51 and often a single trial will aspire to incorporate both aspects. Typically, the challenge for trials with a predominantly explanatory aim is whether the effect estimates based on ideal conditions and selective patients can be reproduced in real-life clinical settings. However, the challenge for trials with a predominantly pragmatic aim is to disentangle bias from true effects. A tension between the diverse roles of patient blinding in trials with mainly explanatory and pragmatic aims is especially clear in acupuncture trials.
52,53
Bias mechanisms
In trials with patient-reported outcomes, bias due to the lack of patient blinding is mainly caused by a combination of response bias (i.e. a tendency for patients to report symptoms in a way they think is expected), placebo effect, differential attrition and differential co-intervention. Further causes of concern in some trials is treatment switches, i.e. patients allocated to the experimental intervention received the control intervention (or vice versa), or contamination, i.e. patients received unintended experimental treatment. The average impact of these bias mechanisms will likely depend on an interaction between the type of outcome, and patients' and treatment providers' predispositions which may vary considerably. Patients' effect expectations may have been low in the two non-acupuncture trials. 11, 12 Previous trials of Echinacea for the common cold had found no clear effects, 11 and distant healing has an implausible mechanism of action. 12 Furthermore, in both trials patient-provider interaction was limited. The typical acupuncture trial, however, involves repetitive close encounters with nonblinded treatment providers, the penetration of the body surface by needles, an ancient nonbiological background theory which is presented as compatible with modern biology via the gate theory. 54 These procedures may induce high effect expectations and induce a higher degree of bias. Attrition rates and co-intervention rates were modest, though higher in the nonblinded control group. These two types of bias mechanisms will likely partly cancel each other out, with an unpredictable net impact. It appears that in our sample of trials, the main mechanism of bias was the combined influence of response bias and placebo effect. 55 In trials where outcomes are assessed by blinded observers, response bias is not an issue and placebo effects are probably absent or considerably reduced, on average. We had access to results from five such trials (1239 patients), 10, 19, 24, 34, 36 of which two were main trials, 10, 19 providing no indication of bias due to nonblinded patients. However, to exclude the existence of a moderate degree of bias many more trials are needed.
Interpretation of effect size and degree of bias
Conventionally, standardized mean differences of -0.2 are considered small effects, -0.5 medium effects and -0.8 large effects. 56 By these standards, our overall result represents a medium effect. However, a degree of bias should not be interpreted in the same way as a treatment effect. The appropriate question is how much bias is to be expected when patients are nonblinded, not whether that degree of bias represents a clinically worthwhile effect had it been a treatment effect. An average exaggeration of 0.56 standard deviation is: pronounced for interventions with medium 'true' effect sizes of -0.5, i.e. exaggeration of effect by 112%; and sizeable for the minority of interventions with large effect sizes of -0.8, i.e. exaggeration of effect by 70%. Thus, we interpret the degree of average bias as considerable.
Implications
We suggest that patients should be blinded whenever possible, and thus to devote considerable resources to developing and assessing patient blinding procedures, especially in trials with patient-reported outcomes.
Blinding patients is likely also important for trials with observer-reported outcomes, but the empirical evidence is less clear and the degree of bias may be less pronounced. Patient blinding is sometimes not possible, for example in trials of exercise, surgery or psychotherapy, or not regarded appropriate in trials with a predominantly pragmatic aim. Our results provide a tentative empirical framework for interpretation of results from such trials.
We emphasize that it is important not only to note the average degree of bias we have found, but also its range and variation. We are therefore sceptical of devising a uniform correction factor for compensating the expected bias in trials without patient blinding.
In conclusion, based on within-trial comparisons, this study provides empirical evidence of pronounced bias due to lack of patient blinding in complementary/alternative randomized clinical trials with patient-reported outcomes.
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